Antibody Step Improves Alzheimer's Blood Test Reliability

Separating Brain-Derived Tau from Peripheral Tissue

A study published in Nature Communications shows that an added antibody preparation step improves the accuracy of blood tests for Alzheimer's disease. Standard commercial blood assays evaluate phosphorylated tau 217 (p-tau217), a protein marker that rises during early disease progression. However, elevated p-tau217 measurements also occur in unrelated peripheral disorders, creating false-positive signals.

The tau protein exists in multiple distinct molecular sizes throughout human tissue. Smaller variants known as brain-derived tau reside primarily in the central nervous system. A larger variant called big tau appears in peripheral nerves and muscle tissues. Standard diagnostic assays do not separate these forms, which allows tau originating outside the skull to distort test scores.

Study Compares Conventional Tests Across 315 Patient Samples

Researchers at University Medicine Halle tested the two-step assay against conventional testing across 315 patient blood samples. The study evaluated 101 individuals diagnosed with Alzheimer's disease, 139 individuals with amyotrophic lateral sclerosis (ALS), and 75 control participants. Clinical teams gathered the blood samples from neurological centers located in Halle and Mannheim, Germany, as well as Milan, Italy.

Standard testing showed increased p-tau217 concentrations in both the Alzheimer's disease group and the ALS cohort. Introducing the specialized antibody to capture brain-derived tau altered that outcome entirely. Following the antibody isolation step, p-tau217 elevations appeared only in individuals with Alzheimer's disease, remaining baseline in the ALS and control cohorts.

Mass Spectrometry Confirms Tissue Origin of Tau Biomarkers

Mass spectrometry analysis verified that brain-derived p-tau217 does not originate from skeletal muscle tissue. The research team evaluated tissue specimens from the human brain, spinal cord, and peripheral muscle groups. Brain-derived p-tau217 was virtually absent in the muscle samples, confirming that the isolated signal corresponds to neurological changes inside the brain.

This laboratory finding explains why general assays pick up misleading signals in individuals with motor neuron diseases. When muscle or peripheral nerve tissues break down, they release non-brain tau into general circulation. Isolating the specific neurological fraction ensures that peripheral tissue breakdown does not mimic cognitive disease.

Clinical Role in Early Diagnosis and Treatment Selection

Accurate blood measurements are necessary to qualify candidates for recently approved antibody therapies that target early-stage Alzheimer's disease. These medical therapies require administration before severe cognitive deficits and extensive short-term memory impairments develop. Misidentifying peripheral nerve disease as Alzheimer's disease could expose individuals to unnecessary treatments while missing their primary condition.

The study authors propose applying the two-step protocol alongside existing diagnostic pathways rather than replacing them immediately. A standard p-tau217 assay can serve as an initial screen in routine diagnostic evaluations. If the result conflicts with a patient's physical presentation, or if an underlying neuromuscular condition exists, the secondary antibody extraction step resolves the discrepancy.